Comparison of fluoroquinolones: Cytotoxicity on human corneal epithelial cells

Eye

Volumn 24, Issue 5, 2010, Pages 909-917

  Tsai, T H ^a   Chen, W L ^a   Hu, F R ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Cornea; Cytotoxicity; Fluoroquinolones; MTS; Transepithelial electrical resistance

Indexed keywords

3 (4,5 DIMETHYLTHIAZOL 2 YL) 5 (3 CARBOXYMETHOXYPHENYL) 2 (4 SULFOPHENYL) 2H TETRAZOLIUM; BENZALKONIUM CHLORIDE; CEFAZOLIN; CIPROFLOXACIN; EYE DROPS; GATIFLOXACIN; GENTAMICIN; LEVOFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; OFLOVID; OFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRAZOLIUM; UNCLASSIFIED DRUG;

ARTICLE; CELL MEMBRANE PERMEABILITY; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; CORNEA EPITHELIUM; DRUG CYTOTOXICITY; DRUG EFFECT; ELECTRIC RESISTANCE; HUMAN; HUMAN CELL; INCUBATION TIME;

EID: 77952499041     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2009.179     Document Type: Article

References (43)

1. Fong CF, Tseng CH, Hu FR, Wang IJ, Chen WL, Hou YC. Clinical characteristics of microbial keratitis in a university hospital in Taiwan. Am J Ophthalmol 2004;137(2):329-336.
2. Smith A, Pennefather PM, Kaye SB, Hart CA. Fluoroquinolones: place in ocular therapy. Drugs 2001;61(6):747-761.
3. Blondeau JM. A review of clinical trials with fluoroquinolones with an emphasis on new agents. Expert Opin Investig Drugs 2000;9(2):383-413.
4. Blondeau JM. Fluoroquinolones: mechanism of action, classification, and development of resistance. Surv Ophthalmol 2004;49 (Suppl 2):S73-S78.
5. Dong Y, Xu C, Zhao X, Domagala J, Drlica K. Fluoroquinolone action against mycobacteria: effects of C-8 substituents on growth, survival, and resistance. Antimicrob Agents Chemother 1998;42(11):2978-2984.
6. Goldstein MH, Kowalski RP, Gordon YJ. Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review. Ophthalmology 1999;106(7):1313-1318.
7. Chaudhry NA, Flynn Jr HW, Murray TG, Tabandeh H, Mello Jr MO, Miller D. Emerging ciprofloxacin-resistant Pseudomonas aeruginosa. Am J Ophthalmol 1999;128(4):509-510.
8. Alexandrakis G, Alfonso EC, Miller D. Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones. Ophthalmology 2000;107(8):1497-1502.
9. Hamam RN, Noureddin B, Salti HI, Haddad R, Khoury JM. Recalcitrant post-LASIK Mycobacterium chelonae keratitis eradicated after the use of fourth-generation fluoroquinolone. Ophthalmology 2006;113(6):950-954.
10. Sarayba MA, Shamie N, Reiser BJ, Sweet PM, Taban M, Graff JM et al Fluoroquinolone therapy in Mycobacterium chelonae keratitis after lamellar keratectomy. J Cataract Refract Surg 2005;31(7):1396-1402.
11. Lee SB, Oliver KM, Strube YN, Mohan SK, Slomovic AR. Fourth-generation fluoroquinolones in the treatment of mycobacterial infectious keratitis after laser-assisted in situ keratomileusis surgery. Can J Ophthalmol 2005;40(6):750-753.
12. Moshirfar M, Mirzaian G, Feiz V, Kang PC. Fourthgeneration fluoroquinolone-resistant bacterial keratitis after refractive surgery. J Cataract Refract Surg 2006;32(3):515-518.
13. Moshirfar M, Feiz V, Vitale AT, Wegelin JA, Basavanthappa S, Wolsey DH. Endophthalmitis after uncomplicated cataract surgery with the use of fourth-generation fluoroquinolones: a retrospective observational case series. Ophthalmology 2007;114(4):686-691.
14. Thibodeaux BA, Dajcs JJ, Caballero AR, Marquart ME, Girgis DO, O'Callaghan RJ. Quantitative comparison of fluoroquinolone therapies of experimental Gram-negative bacterial keratitis. Curr Eye Res 2004;28(5):337-342.
15. Constantinou M, Daniell M, Snibson GR, Vu HT, Taylor HR. Clinical efficacy of moxifloxacin in the treatment of bacterial keratitis: a randomized clinical trial. Ophthalmology 2007;114(9):1622-1629.
16. Dajcs JJ, Thibodeaux BA, Marquart ME, Girgis DO, Traidej M, O'Callaghan RJ. Effectiveness of ciprofloxacin, levofloxacin, or moxifloxacin for treatment of experimental Staphylococcus aureus keratitis. Antimicrob Agents Chemother 2004;48(6):1948-1952.
17. Aliprandis E, Ciralsky J, Lai H, Herling I, Katz HR. Comparative efficacy of topical moxifloxacin versus ciprofloxacin and vancomycin in the treatment of Paeruginosa and ciprofloxacin-resistant MRSA keratitis in rabbits. Cornea 2005;24(2):201-205.
18. Jensen H, Zerouala C, Carrier M, Short B. Comparison of ophthalmic gatifloxacin 0.3% and ciprofloxacin 0.3% in healing of corneal ulcers associated with Pseudomonas aeruginosa-induced ulcerative keratitis in rabbits. J Ocul Pharmacol Ther 2005;21(1):36-43.
19. Kim SY, Lim JA, Choi JS, Choi EC, Joo CK. Comparison of antibiotic effect and corneal epithelial toxicity of levofloxacin and moxifloxacin in vitro. Cornea 2007;26(6):720-725.
20. Kowalski RP, Dhaliwal DK, Karenchak LM, Romanowski EG, Mah FS, Ritterband DC et al Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol 2003;136(3):500-505.
21. Burka JM, Bower KS, Vanroekel RC, Stutzman RD, Kuzmowych CP, Howard RS. The effect of fourthgeneration fluoroquinolones gatifloxacin and moxifloxacin on epithelial healing following photorefractive keratectomy. Am J Ophthalmol 2005;140(1):83-87.
22. Kovoor TA, Kim AS, McCulley JP, Cavanagh HD, Jester JV, Bugde AC et al Evaluation of the corneal effects of topical ophthalmic fluoroquinolones using in vivo confocal microscopy. Eye Contact Lens 2004;30(2):90-94.
23. Ly LT, Cavanagh HD, Petroll WM. Confocal assessment of the effects of fourth-generation fluoroquinolones on the cornea. Eye Contact Lens 2006;32(4):161-165.
24. Williams KK, Shepard AR, Rice RL, McCartney MD, Wax MB, Hiddemen JW. Corneal wound healing in New Zealand white rabbits following anterior keratectomy and treatment with moxifloxacin ophthalmic solution 0.5% or gatifloxacin ophthalmic solution 0.3%. J Ocul Pharmacol Ther 2007;23(6):517-525.
25. Barequet IS, Habot-Wilner Z, Lavinsky F, Ziv H, Belkin M, Rosner M. Effect of fourth-generation fluoroquinolones on the healing rate of corneal erosions in an animal model. Cornea 2007;26(5):606-609.
26. Herrygers LA, Noecker RJ, Lane LC, Levine JM. Comparison of corneal surface effects of gatifloxacin and moxifloxacin using intensive and prolonged dosing protocols. Cornea 2005;24(1):66-71.
27. McGee DH, Holt WF, Kastner PR, Rice RL. Safety of moxifloxacin as shown in animal and in vitro studies. Surv Ophthalmol 2005;50 (Suppl 1):S46-S54.
28. Walter K, Tyler ME. Severe corneal toxicity after topical fluoroquinolone therapy: report of two cases. Cornea 2006;25(7):855-857.
29. Fukuda M, Inoue A, Sasaki K, Takahashi N. The effect of the corneal epithelium on the intraocular penetration of fluoroquinolone ophthalmic solution. Jpn J Ophthalmol 2004;48(2):93-96.
30. Cha SH, Lee JS, Oum BS, Kim CD. Corneal epithelial cellular dysfunction from benzalkonium chloride (BAC) in vitro. Clin Experiment Ophthalmol 2004;32(2):180-184.
31. Dutot M, Pouzaud F, Larosche I, Brignole-Baudouin F, Warnet JM, Rat P. Fluoroquinolone eye drop-induced cytotoxicity: role of preservative in P2X7 cell death receptor activation and apoptosis. Invest Ophthalmol Vis Sci 2006;47(7):2812-2819.
32. Sugrue SP, Zieske JD. ZO1 in corneal epithelium: association to the zonula occludens and adherens junctions. Exp Eye Res 1997;64(1):11-20.
33. Yi X, Wang Y, Yu FS. Corneal epithelial tight junctions and their response to lipopolysaccharide challenge. Invest Ophthalmol Vis Sci 2000;41(13):4093-4100.
34. Toropainen E, Ranta VP, Talvitie A, Suhonen P, Urtti A. Culture model of human corneal epithelium for prediction of ocular drug absorption. Invest Ophthalmol Vis Sci 2001;42(12):2942-2948.
35. Scuderi AC, Paladino GM, Marino C, Trombetta F. In vitro toxicity of netilmicin and ofloxacin on corneal epithelial cells. Cornea 2003;22(5):468-472.
36. Marino C, Paladino GM, Scuderi AC, Trombetta F, Mugridge K, Enea V. In vivo toxicity of netilmicin and ofloxacin on intact and mechanically damaged eyes of rabbit. Cornea 2005;24(6):710-716.
37. Leonardi A, Papa V, Fregona I, Russo P, De Franchis G, Milazzo G. In vitro effects of fluoroquinolone and aminoglycoside antibiotics on human keratocytes. Cornea 2006;25(1):85-90.
38. Mallari PL, McCarty DJ, Daniell M, Taylor H. Increased incidence of corneal perforation after topical fluoroquinolone treatment for microbial keratitis. Am J Ophthalmol 2001;131(1):131-133.
39. Wilhelmus KR, Abshire RL. Corneal ciprofloxacin precipitation during bacterial keratitis. Am J Ophthalmol 2003;136(6):1032-1037.
40. Eiferman RA, Snyder JP, Nordquist RE. Ciprofloxacin microprecipitates and macroprecipitates in the human corneal epithelium. J Cataract Refract Surg 2001;27(10):1701-1702.
41. Konishi M, Yamada M, Mashima Y. Corneal ulcer associated with deposits of norfloxacin. Am J Ophthalmol 1998;125(2):258-260.
42. Matsumoto S, Way W, Tarlo K, Short B. Comparative toxicity of fluoroquinolone antibiotics on corneal cells in vitro. Cornea 2006;25 (2):S1-S7.
43. Saarinen-Savolainen P, Jarvinen T, Araki-Sasaki K, Watanabe H, Urtti A. Evaluation of cytotoxicity of various ophthalmic drugs, eye drop excipients and cyclodextrins in an immortalized human corneal epithelial cell line. Pharm Res 1998;15(8):1275-1280.